Simvastatin Therapy for Moderate and Severe COPD (STATCOPE)

This study has been terminated.
National Heart, Lung, and Blood Institute (NHLBI)
Canadian Institutes of Health Research (CIHR)
Ottawa Hospital Research Institute
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute Identifier:
First received: February 2, 2010
Last updated: March 12, 2015
Last verified: March 2015

To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do not have other indications for statin treatment.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: simvastatin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)

Resource links provided by NLM:

Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • Rates of COPD Exacerbations [ Time Frame: up to 37 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to First COPD Exacerbation [ Time Frame: up to 37 months ] [ Designated as safety issue: No ]
  • Change in FEV1 (% Pred) From Baseline to Last Measure [ Time Frame: Baseline, last measure at up to 37 months ] [ Designated as safety issue: No ]
  • Acute Exacerbation COPD Hospitalization Rates (Events/Patient Year) [ Time Frame: up to 37 months ] [ Designated as safety issue: No ]
  • Systemic and Lung-specific Biomarkers of Inflammation and Procoagulant Activity [ Time Frame: up to 37 months ] [ Designated as safety issue: No ]
  • Rate of Combined Cardiovascular Events [ Time Frame: up to 37 months ] [ Designated as safety issue: No ]
  • The Effect of Current Smoking Status on Inflammatory Biomarker Levels and Response to Simvastatin Treatment [ Time Frame: up to 37 months ] [ Designated as safety issue: No ]
  • Pharmacogenetics and Pharmacoepigenetics of Statin Therapy in COPD [ Time Frame: one time point within study period ] [ Designated as safety issue: No ]

Enrollment: 885
Study Start Date: March 2010
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: simvastatin
40 mgms of simvastatin daily
Drug: simvastatin
40 mgms of simvastatin daily
Other Name: Zocor
Placebo Comparator: placebo
Matched placebo pill daily
Drug: Placebo
Matched placebo pill daily
Other Name: sugar pill

Detailed Description:

COPD exacerbation is a common complication that significantly contributes to the high morbidity, mortality and costs associated with COPD. COPD exacerbations are associated with heightened lung inflammation that may have systemic implications (e.g., peripheral muscle weakness, cognitive impairment, depression, stroke, acute coronary syndrome, and atherosclerosis). Statins are potent agents that significantly reduce vascular events in patients with increased risks due to prior cardiac or cerebral vascular events and elevated lipid profiles. Statins have pleiotropic effects that extend well beyond their lipid lowering effects and may be potent anti-inflammatory agents. Retrospective data conducted in COPD patients indicate that statin use is associated with markedly decreased rates of COPD hospitalization and stabilization of lung function. Decreases in mortality in COPD due to complications of flu-like illnesses and deaths due to cardiovascular events have also been reported. Inflammatory biomarkers (C-reactive protein and interleukin- 6) are reported to be elevated in moderate to severe COPD patients who are prone to exacerbations. Inflammatory biomarkers (C-reactive protein and interleukin- 6) are reported to be reduced by statin therapy in patients with hyperlipidemia and cardiovascular diseases. Treatments that can effectively lessen the prevalence and severity of COPD exacerbations are desperately needed


Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects, 40-80 years of age.
  2. Clinical diagnosis of at least moderate COPD as defined by the GOLD criteria:

    1. Postbronchodilator FEV1(forced expiratory volume at one second)/FVC(forced vital capacity) < 70%,
    2. Postbronchodilator FEV1 (forced expiratory volume at one second) < 80% predicted, with or without chronic symptoms (i.e., cough, sputum production).
  3. Cigarette consumption of 10 pack-years or more. Patients may or may not be active smokers.
  4. Must meet one or more of the following 4 conditions

    1. Be using supplemental oxygenate
    2. Receiving a course of systemic corticosteroids and/or antibiotics for respiratory problems in the past year,
    3. Visiting an Emergency Department for a COPD exacerbation within the past year, or
    4. Being hospitalized for a COPD (Chronic Obstructive Pulmonary Disease) exacerbation within the past year
  5. Willingness to make return visits and availability by telephone for duration of study.
  6. Free of active coronary disease
  7. Subject with expected life expectancy > 36 months

Exclusion Criteria:

  1. Patients who:

    1. are on statin drugs.
    2. should be on statins based on established risk stratification using the ATP-III (Adult Treatment Panel) to determine 10 year risk.
  2. Documented history of active coronary heart disease, such as unstable angina, prior myocardial infarction, stroke, symptomatic peripheral vascular or carotid artery disease, or congestive heart failure within the past 3 months.
  3. A diagnosis of asthma.
  4. The presence of a diagnosis other than COPD that results in the patient being either medically unstable, or having a predicted life expectancy < 3 years.
  5. Special patient groups: prisoners, pregnant women, institutionalized patients
  6. Women who are at risk of becoming pregnant during the study (pre-menopausal) and who refuse to use acceptable birth control (hormone-based oral or barrier contraceptive) for the duration of the study.
  7. Woman using estradiol compounds for contraception. Postmenopausal women on estradiol compounds for hormone replacement therapy will be allowed into the trial.
  8. Participants otherwise meeting the inclusion criteria will not be enrolled until they are a minimum of four weeks from their most recent acute exacerbation.
  9. A clinical diagnosis of bronchiectasis defined as production of > one-half cup of purulent sputum/day.
  10. Participants using niacin, azole antifungals (itraconazole, ketoconazole, posaconazole), fibric acid derivatives, erythromycin, clarithromycin, telithromycin, diltiazem, amlodipine , ranolazine,HIV protease inhibitors (such as indinavir), amiodarone, gemfibrozil, cyclosporine, verapamil, danazol, nefazodone, and red yeast rice extracts are excluded
  11. Active liver disease. Active liver disease is defined as ALT (alanine aminotransferase), AST (aspartate aminotransferase) as greater than 1.5 times the upper limit of normal.
  12. Patients with renal failure defined by serum creatinine greater than 3mg/dl.
  13. Alcoholism. Alcoholism is defined as > 35 drinks per week. A drink is defined as one bottle of beer, one 8-ounce glass of wine, or one ounce of hard liquor.
  14. Hypersensitivity to HMG CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors. Hypersensitivity is defined as an allergic reaction to statin, prior history of myopathy, rhabdomyolysis or previous intolerance to statin use.
  15. Participants drinking greater than 4 cups (1qt) of grapefruit juice per day.
  16. Participants drinking greater than 3 cups of green tea per day.
  17. Diabetics will be excluded. Diabetics are defined by:

1. A CURRENT physician diagnosis of diabetes OR 2. CURRENT use of diabetic meds OR 3. Elevated HbA1c > 6.5% 18. The discretion of the Principal Investigator that the potential participant will not be a reliable study subject to complete the study requirements.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01061671

  Hide Study Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Veteran's Administration Medical Center
Birmingham, Alabama, United States, 35294
United States, California
LA BioMed at Harbor-UCLA Medical Center
Los Angeles, California, United States, 90502
University of California at San Francisco
San Francisco, California, United States, 94143
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
National Jewish Health
Denver, Colorado, United States, 80206
United States, Florida
Malcom Randall VA Medical Center
Gainesville, Florida, United States, 32608
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
University of Illinois Health System
Chicago, Illinois, United States, 60637
United States, Louisiana
LSU Health
New Orleans, Louisiana, United States, 70112
United States, Maryland
University of Maryland Baltimore
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Veteran's Administration Medical Center
Boston, Massachusetts, United States, 02132
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Reliant Medical Group
Worcester, Massachusetts, United States, 01608
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Veteran's Administration Medical Center
Ann Arbor, Michigan, United States, 48105
United States, Minnesota
HealthPartners Research Foundation
Minneapolis, Minnesota, United States, 55440
Veteran's Administration Medical Center
Minneapolis, Minnesota, United States, 55417
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Mexico
Lovelace Respiratory Research Institute
Albuquerque, New Mexico, United States, 87108
United States, New York
Western New York Veterans Administration Healthcare System
Buffalo, New York, United States, 14125
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
United States, Ohio
Cincinnati VAMC
Cincinnati, Ohio, United States, 45220
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Ohio State University
Columbus, Ohio, United States, 43221
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, United States, 18015
Geisinger Medical Center
Danville, Pennsylvania, United States, 17822
Institute for Respiratory and Sleep
Langhorne, Pennsylvania, United States, 19047
Temple University Lung Center
Philadelphia, Pennsylvania, United States, 19140
Pittsburgh VA Medical Center
Pittsburgh, Pennsylvania, United States, 15240
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Respiratory Specialists
Wyomissing, Pennsylvania, United States, 19601
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Utah
University of Utah Health Sciences Center
Salt Lake City, Utah, United States, 84132
Canada, Alberta
University of Calgary
Calgary, Alberta, Canada, T2N4Z6
University of Alberta
Edmonton, Alberta, Canada, T6G 2C8
Canada, British Columbia
Royal Columbian Hospital
New Westminster, British Columbia, Canada
Surrey Memorial Hospital
Surrey, British Columbia, Canada, V3V1N1
St. Paul's Hospital
Vancouver, British Columbia, Canada, V6Z 1Y6
Lion's Gate Hospital
Vancouver, British Columbia, Canada, V7M2H9
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z1M9
Canada, Manitoba
St. Boniface Hospital
Winnipeg, Manitoba, Canada, R2H2A6
Canada, Nova Scotia
Queen Elizabeth II Health Sciences Center
Halifax, Nova Scotia, Canada, B3H 3A7
Canada, Ontario
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 4A6
Ottawa Civic Hospital
Ottawa, Ontario, Canada, K1Y4E9
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Inspiration Research Limited
Toronto, Ontario, Canada, M5T 3A9
Canada, Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Canada, Saskatchewan
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8
Institut Universitaire de Cardiologie et de Pneumologie de Québec (Laval Hospital)
Quebec, Canada, G1V 4G5
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
National Heart, Lung, and Blood Institute (NHLBI)
Canadian Institutes of Health Research (CIHR)
Ottawa Hospital Research Institute
Principal Investigator: John E Connett, PhD University of Minnesota (Data Coordinating Center)
Principal Investigator: Steven M Scharf, MD, PhD University of Maryland, Baltimore County
Principal Investigator: Mark Dransfield, MD University of Alabama at Birmingham
Principal Investigator: George Washko, MD Brigham and Women's Hospital Boston
Principal Investigator: Richard K Albert, MD Denver Health Medical Center
Principal Investigator: Richard Casaburi, MD, PhD Harbor-UCLA Research & Education Institute
Principal Investigator: Dennis E Niewoehner, MD Minnesota Veterans Affairs Medical Center
Principal Investigator: Gerard J Criner, MD Temple University Philadelphia
Principal Investigator: Frank Sciurba, MD University of Pittsburgh
Principal Investigator: Stephen C Lazarus, MD University of California at San Francisco
Principal Investigator: Fernando J Martinez, MD University of Michigan
Principal Investigator: Don Sin, M.D. St. Paul's Hospital
Principal Investigator: Shawn Aaron, M.D. The Ottawa Hospital
  More Information

No publications provided by University of Minnesota - Clinical and Translational Science Institute

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Minnesota - Clinical and Translational Science Institute Identifier: NCT01061671     History of Changes
Other Study ID Numbers: 689, U10HL074424
Study First Received: February 2, 2010
Results First Received: January 29, 2015
Last Updated: March 12, 2015
Health Authority: United States: Federal Government
Canada: Health Canada

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
Chronic Obstructive Pulmonary Disease
Lung function

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Lung Diseases, Obstructive
Pathologic Processes
Respiratory Tract Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on October 07, 2015